Bio-Path Holdings, Inc.(BPTH)

$0.00—

Ask SA Chart

Bio-Path Holdings, Inc.(BPTH)

NASDAQ

$0.00—

Ask SA Chart Studio

BPTH(BPTH)

BPTH

9/23/26

Bio-Path (BPTH)

Wednesday

11:12 AM

ThesisPositive clinical trial results and potential partnerships are shifting investor sentiment towards a more optimistic outlook for Bio-Path.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$0.00	$40M	$40M
Rev. Growth	—	—	-0.5%
EPS	$-1.10	$-1.42	$-1.37
EPS Growth	+73.3%	-29.1%	+3.5%
P/E	—	—	—

★ Analysts see FY2027 revenue reaching $40M — -0.5% growth in a single year.

What’s Driving the Stock

01Recent Phase 1 trial results for BP1001 showed a 60% response rate in AML patients, indicating strong potential for Phase 2 trials.
02The company is in discussions for a strategic partnership with a major pharmaceutical firm, which could provide funding and market access.
03Increased investor interest in targeted cancer therapies has led to a surge in biotech funding, potentially benefiting Bio-Path.
04Targeted cancer therapies gaining traction in the market
05Increased investment in biotechnology R&D
06Clinical trial results for BP1001, particularly Phase 2 data
07Regulatory approvals from the FDA for new drug applications
08Partnerships or collaborations with larger pharmaceutical companies

FY2025 Snapshot

Revenue: $0.00
Gross Margin: 0.0%
Op. Margin: 0.0%
Net Margin: 0.0%
Net Income: $-9M
NI Growth: +12.3%
EPS: $-1.10
1Y Return: -99.1%

BPTH Chart

My Notes

"Management highlighted the 'promising data' from recent trials as a catalyst for future growth."
Moat: Bio-Path's proprietary DNAbilize technology provides a unique delivery mechanism that differentiates it from competitors.
growth - Investors looking for high-risk, high-reward opportunities in the biotechnology sector.
Moderate - Rising interest rates can increase the cost of capital for funding clinical trials and R&D…
Watch on earnings: Clinical trial enrollment rates, Cash runway (months until funding is needed), Partnership announcements.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $40M to $40M as recent phase 1 trial results for bp1001 showed a 60% response rate in aml patients.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2025

FY2026E

FY2027E

—

P/E

—

What’s Driving the Stock

01Recent Phase 1 trial results for BP1001 showed a 60% response rate in AML patients, indicating strong potential for Phase 2 trials.

02The company is in discussions for a strategic partnership with a major pharmaceutical firm, which could provide funding and market access.

03Increased investor interest in targeted cancer therapies has led to a surge in biotech funding, potentially benefiting Bio-Path.

04Targeted cancer therapies gaining traction in the market

05Increased investment in biotechnology R&D

06Clinical trial results for BP1001, particularly Phase 2 data

07Regulatory approvals from the FDA for new drug applications

08Partnerships or collaborations with larger pharmaceutical companies

My Notes

"Management highlighted the 'promising data' from recent trials as a catalyst for future growth."

Moat: Bio-Path's proprietary DNAbilize technology provides a unique delivery mechanism that differentiates it from competitors.

growth - Investors looking for high-risk, high-reward opportunities in the biotechnology sector.

Moderate - Rising interest rates can increase the cost of capital for funding clinical trials and R&D…

Watch on earnings: Clinical trial enrollment rates, Cash runway (months until funding is needed), Partnership announcements.